Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 214

1.

Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, Lashley T, Kallis C, Williams DR, de Silva R, Lees AJ, Revesz T.

Brain. 2011 May;134(Pt 5):1493-505. doi: 10.1093/brain/awr031.

2.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
21317042
3.

Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia.

Fujishiro H, Iseki E, Higashi S, Kasanuki K, Murayama N, Togo T, Katsuse O, Uchikado H, Aoki N, Kosaka K, Arai H, Sato K.

Neurosci Lett. 2010 Dec 3;486(1):19-23. doi: 10.1016/j.neulet.2010.09.036. Epub 2010 Sep 17.

PMID:
20851165
4.

Confluence of α-synuclein, tau, and β-amyloid pathologies in dementia with Lewy bodies.

Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, Martí MJ, Clarimón J, Lleó A.

J Neuropathol Exp Neurol. 2013 Dec;72(12):1203-12. doi: 10.1097/NEN.0000000000000018.

PMID:
24226269
5.

Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias.

Howlett DR, Whitfield D, Johnson M, Attems J, O'Brien JT, Aarsland D, Lai MK, Lee JH, Chen C, Ballard C, Hortobágyi T, Francis PT.

Brain Pathol. 2015 Jul;25(4):401-8. doi: 10.1111/bpa.12182. Epub 2014 Oct 30.

PMID:
25103200
6.

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis.

Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, Nelson PT, Jicha GA, Woltjer R, Quinn JF, Kaye J, Leverenz JB, Tsuang D, Longfellow K, Yearout D, Kukull W, Keene CD, Montine TJ, Zabetian CP, Trojanowski JQ.

Lancet Neurol. 2017 Jan;16(1):55-65. doi: 10.1016/S1474-4422(16)30291-5.

7.

The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia.

Compta Y, Parkkinen L, Kempster P, Selikhova M, Lashley T, Holton JL, Lees AJ, Revesz T.

Neurodegener Dis. 2014;13(2-3):154-6. doi: 10.1159/000354670. Epub 2013 Sep 11.

8.

Pathologic accumulation of α-synuclein and Aβ in Parkinson disease patients with dementia.

Kotzbauer PT, Cairns NJ, Campbell MC, Willis AW, Racette BA, Tabbal SD, Perlmutter JS.

Arch Neurol. 2012 Oct;69(10):1326-31.

9.

Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease.

Jellinger KA, Attems J.

Acta Neuropathol. 2008 Apr;115(4):427-36. doi: 10.1007/s00401-008-0347-5. Epub 2008 Feb 14.

PMID:
18273624
10.

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.

Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O.

Mov Disord. 2011 Jul;26(8):1428-35. doi: 10.1002/mds.23670. Epub 2011 Apr 5.

PMID:
21469206
11.

Neuropathologic substrates of Parkinson disease dementia.

Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, Lee VM, Leverenz JB, Montine TJ, Duda JE, Hurtig HI, Trojanowski JQ.

Ann Neurol. 2012 Oct;72(4):587-98. doi: 10.1002/ana.23659. Epub 2012 Oct 4.

12.

A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.

Jellinger KA.

Biochim Biophys Acta. 2009 Jul;1792(7):730-40. doi: 10.1016/j.bbadis.2008.07.006. Epub 2008 Aug 5. Review.

13.

Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes.

Walker L, McAleese KE, Thomas AJ, Johnson M, Martin-Ruiz C, Parker C, Colloby SJ, Jellinger K, Attems J.

Acta Neuropathol. 2015 May;129(5):729-48. doi: 10.1007/s00401-015-1406-3. Epub 2015 Mar 11.

PMID:
25758940
14.

Correlations between cortical and subcortical tau pathology.

Attems J, Thomas A, Jellinger K.

Neuropathol Appl Neurobiol. 2012 Oct;38(6):582-90. doi: 10.1111/j.1365-2990.2011.01244.x.

PMID:
22115520
15.

Limbic neuropathology in idiopathic Parkinson's disease with concomitant dementia.

Bertrand E, Lechowicz W, Szpak GM, Lewandowska E, Dymecki J, Wierzba-Bobrowicz T.

Folia Neuropathol. 2004;42(3):141-50.

PMID:
15535032
16.

Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease.

Halliday GM, Song YJ, Harding AJ.

J Neural Transm (Vienna). 2011 May;118(5):713-9. doi: 10.1007/s00702-011-0641-6. Epub 2011 Apr 9.

PMID:
21479514
17.

Morphological substrates of mental dysfunction in Lewy body disease: an update.

Jellinger KA.

J Neural Transm Suppl. 2000;59:185-212.

PMID:
10961431
18.

Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies.

Llorens F, Schmitz M, Varges D, Kruse N, Gotzmann N, Gmitterová K, Mollenhauer B, Zerr I.

J Neurol. 2016 Nov;263(11):2271-2277. Epub 2016 Aug 20.

PMID:
27544498
19.

Tau pathology in the olfactory bulb correlates with Braak stage, Lewy body pathology and apolipoprotein epsilon4.

Tsuboi Y, Wszolek ZK, Graff-Radford NR, Cookson N, Dickson DW.

Neuropathol Appl Neurobiol. 2003 Oct;29(5):503-10.

PMID:
14507342
20.

Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline.

Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM.

J Neurosci. 2010 May 26;30(21):7281-9. doi: 10.1523/JNEUROSCI.0490-10.2010.

Supplemental Content

Support Center